Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne ...

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

Beyond DMD, REGENXBIO's ocular gene therapy programs represent another significant avenue for growth. The company's RGX-314 candidate for wet AMD and DR has shown progress, with Phase 2 trials ...

A key factor is the potential of RegenXBio’s gene therapy approach for VEGF-mediated diseases, which addresses significant unmet needs. However, Frommer notes that the current methods of delivery, ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and increased the price target to ...

Morgan Stanley emphasized the importance of continued monitoring of Regenxbio's gene therapy programs. The firm is particularly interested in the exploration of a fourth dose level for ...

With a diverse pipeline targeting high-value indications such as Duchenne muscular dystrophy (DMD) and wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), REGENXBIO has positioned itself as a ...